insights_auto
Why is GNLX down 2.31%?
Dive Deeperchevron_right
GNLX:NASDAQ
Genelux Corp
$2.54
arrow_downward
-2.31%(-0.060) 1D
$2.54
0.00% (0.00)
todayPre-market
Closed: Oct 6, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
$2.58
High
$2.63
Low
$2.52
Mkt. cap
113.16M
Avg. vol.
279.66K
Volume
200.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
Open
$2.58
High
$2.63
Low
$2.52
Mkt. cap
113.16M
Avg. vol.
279.66K
Volume
200.00
52-wk high
$8.54
52-wk low
$2.29
EPS
-$0.87
Beta
0.59
Shares outstanding
45.24M
No. of employees
26
News stories
From web sources and news partners
PR Newswire
·
26 minutes ago
Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance
Yahoo Finance
·
1 hour ago
AST SpaceMobile (ASTS) Completed Its First Direct Satellite To Smartphone Test In Canada
WBOC TV
·
2 hours ago
VivoSim (NASDAQ: VIVS) NAMkind™ Targets FDA’s New Testing Bar
CNBC
·
47 minutes ago
AI trade driving stocks, but questions remain over rest of market
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitegenelux.com